Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease

Huntington Study Group TREND-HD Investigators, The TREND-HD Study

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves the motor features of Huntington disease. Design: Six-monthmulticenter,randomized,double-blind, placebo-controlled trial followed by a 6-month open-label phase without disclosing initial treatment assignments. Setting: Forty-one research sites in the United States and Canada. Patients: Three hundred sixteen adults with Huntington disease, enriched for a population with shorter trinucleotide (cytosine-adenine-guanine) repeat length expansions. Interventions: Random assignment to placebo or ethyl- EPA, 1 g twice a day, followed by open-label treatment with ethyl-EPA. Main Outcome Measures: Six-month change in the Total Motor Score 4 component of the Unified Huntington’s Disease Rating Scale analyzed for all research participants and those with shorter cytosine-adenineguanine repeat length expansions (< 45). Results: At 6 months, the Total Motor Score 4 point change for patients receiving ethyl-EPA did not differ from that for those receiving placebo. No differences were found in measures of function, cognition, or global impression. Before public disclosure of the 6-month placebo-controlled results, 192 individuals completed the open-label phase. The Total Motor Score 4 change did not worsen for those who received active treatment for 12 continuous months compared with those who received active treatment for only 6 months (2.0-point worsening; P=.02). Conclusion: Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebocontrolled evaluation.

Original languageEnglish (US)
Pages (from-to)1582-1589
Number of pages8
JournalArchives of Neurology
Volume65
Issue number12
DOIs
StatePublished - Jan 1 2008
Externally publishedYes

Fingerprint

Huntington Disease
Randomized Controlled Trials
Placebos
Cytosine
Disclosure
Guanine
Adenine
Therapeutics
Research
Cognition
Canada
Fatty Acids
Outcome Assessment (Health Care)
ethyl eicosapentaenoic acid
Randomized Controlled Trial
Placebo
Population
Controlled
Assignment
Length

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Huntington Study Group TREND-HD Investigators, & The TREND-HD Study (2008). Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease. Archives of Neurology, 65(12), 1582-1589. https://doi.org/10.1001/archneur.65.12.1582

Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease. / Huntington Study Group TREND-HD Investigators; The TREND-HD Study.

In: Archives of Neurology, Vol. 65, No. 12, 01.01.2008, p. 1582-1589.

Research output: Contribution to journalArticle

Huntington Study Group TREND-HD Investigators & The TREND-HD Study 2008, 'Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease', Archives of Neurology, vol. 65, no. 12, pp. 1582-1589. https://doi.org/10.1001/archneur.65.12.1582
Huntington Study Group TREND-HD Investigators, The TREND-HD Study. Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease. Archives of Neurology. 2008 Jan 1;65(12):1582-1589. https://doi.org/10.1001/archneur.65.12.1582
Huntington Study Group TREND-HD Investigators ; The TREND-HD Study. / Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease. In: Archives of Neurology. 2008 ; Vol. 65, No. 12. pp. 1582-1589.
@article{c7ee93c8bcef4ca18e6330de1681e7db,
title = "Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease",
abstract = "Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves the motor features of Huntington disease. Design: Six-monthmulticenter,randomized,double-blind, placebo-controlled trial followed by a 6-month open-label phase without disclosing initial treatment assignments. Setting: Forty-one research sites in the United States and Canada. Patients: Three hundred sixteen adults with Huntington disease, enriched for a population with shorter trinucleotide (cytosine-adenine-guanine) repeat length expansions. Interventions: Random assignment to placebo or ethyl- EPA, 1 g twice a day, followed by open-label treatment with ethyl-EPA. Main Outcome Measures: Six-month change in the Total Motor Score 4 component of the Unified Huntington’s Disease Rating Scale analyzed for all research participants and those with shorter cytosine-adenineguanine repeat length expansions (< 45). Results: At 6 months, the Total Motor Score 4 point change for patients receiving ethyl-EPA did not differ from that for those receiving placebo. No differences were found in measures of function, cognition, or global impression. Before public disclosure of the 6-month placebo-controlled results, 192 individuals completed the open-label phase. The Total Motor Score 4 change did not worsen for those who received active treatment for 12 continuous months compared with those who received active treatment for only 6 months (2.0-point worsening; P=.02). Conclusion: Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebocontrolled evaluation.",
author = "{Huntington Study Group TREND-HD Investigators} and {The TREND-HD Study} and Dorsey, {E. R.} and I. Shoulson and B. Leavitt and C. Ross and Beck, {C. A.} and {de Blieck}, {E. A.} and Greenamyre, {J. T.} and Hersch, {S. M.} and K. Kieburtz and K. Marder and C. McCallum and C. Moskowitz and D. Oakes and A. Rosenblatt and A. Shinaman and S. Frucht and K. Marder and C. Moskowitz and R. Margolis and J. Corey-Bloom and Hersch, {S. M.} and L. Mook and K. Shannon and J. Jaglin and J. Sanchez-Ramos and Dure, {L. S.} and M. Guttman and A. Feigin and B. Shannon and Anderson, {K. E.} and Racette, {B. A.} and D. Higgins and P. Agarwal and L. Seeberger and S. Montellano and S. Kostyk and A. Seward and M. Nance and Raymond, {L. A.} and J. Decolongon and O. Suchowersky and L. Beglinger and H. Paulson and P. Como and R. Barbano and C. Zimmerman and J. Wojcieszek and M. Jog and C. Horn and Morgan, {John Christopher}",
year = "2008",
month = "1",
day = "1",
doi = "10.1001/archneur.65.12.1582",
language = "English (US)",
volume = "65",
pages = "1582--1589",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Randomized controlled trial of ethyl-eicosapentaenoic acid in huntington disease

AU - Huntington Study Group TREND-HD Investigators

AU - The TREND-HD Study

AU - Dorsey, E. R.

AU - Shoulson, I.

AU - Leavitt, B.

AU - Ross, C.

AU - Beck, C. A.

AU - de Blieck, E. A.

AU - Greenamyre, J. T.

AU - Hersch, S. M.

AU - Kieburtz, K.

AU - Marder, K.

AU - McCallum, C.

AU - Moskowitz, C.

AU - Oakes, D.

AU - Rosenblatt, A.

AU - Shinaman, A.

AU - Frucht, S.

AU - Marder, K.

AU - Moskowitz, C.

AU - Margolis, R.

AU - Corey-Bloom, J.

AU - Hersch, S. M.

AU - Mook, L.

AU - Shannon, K.

AU - Jaglin, J.

AU - Sanchez-Ramos, J.

AU - Dure, L. S.

AU - Guttman, M.

AU - Feigin, A.

AU - Shannon, B.

AU - Anderson, K. E.

AU - Racette, B. A.

AU - Higgins, D.

AU - Agarwal, P.

AU - Seeberger, L.

AU - Montellano, S.

AU - Kostyk, S.

AU - Seward, A.

AU - Nance, M.

AU - Raymond, L. A.

AU - Decolongon, J.

AU - Suchowersky, O.

AU - Beglinger, L.

AU - Paulson, H.

AU - Como, P.

AU - Barbano, R.

AU - Zimmerman, C.

AU - Wojcieszek, J.

AU - Jog, M.

AU - Horn, C.

AU - Morgan, John Christopher

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves the motor features of Huntington disease. Design: Six-monthmulticenter,randomized,double-blind, placebo-controlled trial followed by a 6-month open-label phase without disclosing initial treatment assignments. Setting: Forty-one research sites in the United States and Canada. Patients: Three hundred sixteen adults with Huntington disease, enriched for a population with shorter trinucleotide (cytosine-adenine-guanine) repeat length expansions. Interventions: Random assignment to placebo or ethyl- EPA, 1 g twice a day, followed by open-label treatment with ethyl-EPA. Main Outcome Measures: Six-month change in the Total Motor Score 4 component of the Unified Huntington’s Disease Rating Scale analyzed for all research participants and those with shorter cytosine-adenineguanine repeat length expansions (< 45). Results: At 6 months, the Total Motor Score 4 point change for patients receiving ethyl-EPA did not differ from that for those receiving placebo. No differences were found in measures of function, cognition, or global impression. Before public disclosure of the 6-month placebo-controlled results, 192 individuals completed the open-label phase. The Total Motor Score 4 change did not worsen for those who received active treatment for 12 continuous months compared with those who received active treatment for only 6 months (2.0-point worsening; P=.02). Conclusion: Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebocontrolled evaluation.

AB - Objective: To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an ω-3 fatty acid, improves the motor features of Huntington disease. Design: Six-monthmulticenter,randomized,double-blind, placebo-controlled trial followed by a 6-month open-label phase without disclosing initial treatment assignments. Setting: Forty-one research sites in the United States and Canada. Patients: Three hundred sixteen adults with Huntington disease, enriched for a population with shorter trinucleotide (cytosine-adenine-guanine) repeat length expansions. Interventions: Random assignment to placebo or ethyl- EPA, 1 g twice a day, followed by open-label treatment with ethyl-EPA. Main Outcome Measures: Six-month change in the Total Motor Score 4 component of the Unified Huntington’s Disease Rating Scale analyzed for all research participants and those with shorter cytosine-adenineguanine repeat length expansions (< 45). Results: At 6 months, the Total Motor Score 4 point change for patients receiving ethyl-EPA did not differ from that for those receiving placebo. No differences were found in measures of function, cognition, or global impression. Before public disclosure of the 6-month placebo-controlled results, 192 individuals completed the open-label phase. The Total Motor Score 4 change did not worsen for those who received active treatment for 12 continuous months compared with those who received active treatment for only 6 months (2.0-point worsening; P=.02). Conclusion: Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebocontrolled evaluation.

UR - http://www.scopus.com/inward/record.url?scp=61449249687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449249687&partnerID=8YFLogxK

U2 - 10.1001/archneur.65.12.1582

DO - 10.1001/archneur.65.12.1582

M3 - Article

C2 - 19064745

AN - SCOPUS:61449249687

VL - 65

SP - 1582

EP - 1589

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 12

ER -